Maple Capital Management Inc. Has $14.15 Million Stock Position in Zoetis Inc. $ZTS

Maple Capital Management Inc. grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% in the first quarter, Holdings Channel reports. The institutional investor owned 85,918 shares of the company’s stock after acquiring an additional 1,076 shares during the period. Zoetis makes up 1.1% of Maple Capital Management Inc.’s investment portfolio, making the stock its 28th largest holding. Maple Capital Management Inc.’s holdings in Zoetis were worth $14,146,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new position in Zoetis during the first quarter worth about $25,000. 1248 Management LLC bought a new stake in Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank bought a new stake in Zoetis in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after purchasing an additional 120 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.8%

Shares of ZTS stock opened at $150.66 on Friday. The company has a 50 day moving average of $152.53 and a 200-day moving average of $157.45. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The firm has a market cap of $66.77 billion, a P/E ratio of 25.93, a PEG ratio of 2.40 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the business posted $1.56 EPS. Zoetis’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.